Intelligence / B2B SaaS / Acquisitions / Zymeworks Inc.
M&Acompleted an acquisition (SEC 8-K)23 Sept 2026
Zymeworks Inc.
23 Sept 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.
- Filed
- 23 Sept 2026
- Ticker
- ZYME
- Role
- Completed an acquisition
- Sector
- Pharma and biotech
- Sic
- 2834
- Items
- 1.01, 2.01, 2.03, 7.01, 9.01
- Summary
- On September 23, 2026 (the "Closing Date"), Zymeworks Inc., a Delaware corporation ("Zymeworks") completed the previously announced merger contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger, dated June 28, 2026 (the "Merger Agreement"), by and among Zymeworks, Theravance Biopharma, In
- Location
- Middletown, DE
- State
- Delaware
- Country
- United States
- SEC CIK
- 1937653
- Reference
- 0001193125-26-399383
What this signal means
Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.
- Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
- 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS
Find the decision makers at Zymeworks Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.
More in Completed an acquisition
Acquisitions
18 NovAI Era Corp.completed an acquisition (SEC 8-K) · Real estate and investmentM&A18 NovSoundthinking, INC.completed an acquisition (SEC 8-K) · Software and ITM&A17 NovGridAI Technologies Corp.completed an acquisition (SEC 8-K) · Energy and utilitiesM&A17 NovInteger Holdings Corpcompleted an acquisition (SEC 8-K) · Medical devicesM&A17 NovPacira BioSciences, Inc.completed an acquisition (SEC 8-K) · Pharma and biotechM&A17 NovViatris Inccompleted an acquisition (SEC 8-K) · Pharma and biotechM&A
Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.